A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
CD4 count greater than 50 cells/mm3.
HIV RNA less than 50,000 copies/ml.
No active AIDS (excluding CD4 count less than 200 cells/mm3).
Ability to comply with dosing schedule and protocol evaluations.
AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Patients with any of the following symptoms or conditions are excluded:
Active AIDS (not excluding CD4 count less than 200).
Malabsorption syndrome affecting drug absorption.
Serious medical condition that would compromise safety of the patient.
AZT or NNRTIs.
More than 1 week treatment with any protease inhibitor.
Enrollment in any other investigational drug protocol.
Patients with the following prior conditions are excluded:
History of clinically relevant pancreatitis or hepatitis within the past 6 months.
Antiretroviral therapy with either single or double reverse transcriptase inhibitors.
Henry K, Shaeffer M, Ross L, Johnson M, Fisher R, Liao Q, Graham N. Response to Combivir and abacavir given bid to nucleoside experienced patients is not affected by the presence of the M184V mutation. 6th Conf Retro and Opportun Infect. 1999 Jan 31 - Feb 4 (abstract no 132)